Kornimate/medical-research-clean huggingface dataset:
the effect of using music and natural landscape paintings on pain level, anxiety and analgesic use of women during hsg

Conditions: Hysterosalpingography; Anxiety; Pain

Summary: the study was planned as a randomized controlled study in order to evaluate the use of music and natural scenery paintings in women who underwent hsg procedure, their pain level, anxiety and post-procedure analgesic use.

the universe of the research; women who apply to dicle university hospital's obstetrics and gynecology polyclinic will be recommended to have an hsg. sample of the research: women who applied to the dicle university hospital obstetrics and gynecology outpatient clinic and recommended to have an hsg will participate in the study. in the calculation of the sample size of the research, in the calculation made in line with the data taken from the reference studies; the sample size was used at the 95% confidence interval, the effect size was 0.80, and the alpha was 0.05, and it was seen that at least 29 individuals should be included in each group. application of research the study was planned to be conducted on women who were recommended to have an hsg, who applied to the dicle university hospital obstetrics and gynecology clinic between january 2022 and july 2023 in a randomized controlled manner. the socio-demographic data questionnaire, visual pain scale, state-trait anxiety inventory, and the socio-demographic data questionnaire, prepared by the researcher for the women who were selected in accordance with the sample selection criteria and accepted to be a participant, in line with the recommendations of the academicians specialized in the field of gynecology and gynecology nursing. analgesia follow-up form will be applied. after the control group study is completed, the case group study will begin. the reason why the control and case groups were not studied at the same time was because it was thought that women saw each other and would be affected by each other. in the control group, only the pre-test before the procedure, the post-test after the procedure and the use of analgesics within 24 hours after the hsg will be questioned with data collection tools and no attempt will be made. case groups will be pre-tested before the procedure, they will be listened to music or shown pictures of natural landscapes during the procedure, and after the procedure is completed, the post-test will be applied and 24 hours after the procedure, they will be contacted and questioned whether they use analgesics.

Eligibility criteria:
inclusion criteria: * in the research be over 18 years old * at least primary school graduate * not have a diagnosed psychiatric illness * not having mental deficiency and communication problems * no drug sensitivity or allergy * not having received infertility treatment before * being diagnosed with primary infertility exclusion criteria: * to be illiterate be under the age of 18 * having a diagnosed psychiatric illness * mental disability and communication problems * having drug sensitivity and allergy * being diagnosed with secondary infertility

Keywords: hsg music natural landscape anxiety
peak plasmablade™ 4.0 versus traditional electrosurgery in lumpectomy

Conditions: Breast Cancer

Summary: the purpose of this clinical study is to quantify the difference in thermal injury depth at the surgical margin in breast lumpectomy specimens excised with the plasmablade; to subjectively assess histopathologic sample quality metrics; to examine the role that electrosurgical artifact may play in revision lumpectomy procedures; and to compare these endpoints to the standard of care (soc) technology.

lumpectomy is a surgical procedure performed to remove a localized mass of breast tissue that is suspicious for malignancy. the purpose of lumpectomy is to minimize the amount of tissue removed from the breast to retain normal breast architecture while simultaneously removing all of the suspected cancerous tissue. typically, a scalpel is used for the skin incision and a traditional electrosurgical device is used to cut away any cancerous tissue. the peak plasmablade™ uses pulsed radiofrequency (rf) energy and a highly-insulated handpiece design to enable precision cutting and coagulation at the point of application. the plasmablade has received fda clearance for use in plastic, general, and ear, nose, and throat (ent) surgery, and has demonstrated a significantly reduced thermal injury profile in incised tissue compared to traditional electrosurgical devices. it is hypothesized that this benefit may improve the pathological analysis of excised breast lumps. this single site study was granted institutional review board (irb) approval and conducted between june 2009 and january 2011. potential subjects were screened against the inclusion and exclusion criteria of the study protocol and were then required to provide informed consent prior to enrollment. following enrollment, subjects were prospectively randomized to the soc or peak plasmablade study groups and scheduled for lumpectomy.

Eligibility criteria:
inclusion criteria: 1. age between 18 and 90 years old 2. physically healthy, stable weight 3. requiring lumpectomy with wire localization for suspected or confirmed malignant breast disease. 4. subject must understand the nature of the procedure and provide written informed consent prior to the procedure. 5. subject must be willing and able to comply with all follow-up evaluations exclusion criteria: 1. age younger than 18 or greater than 90 years old 2. infection (local or systemic) 3. cognitive impairment or mental illness 4. severe cardiopulmonary deficiencies 5. unable to follow instructions or complete follow-up 6. currently taking any medication known to affect healing 7. currently enrolled in another investigational device or drug trial

Keywords: lumpectomy plasmablade electrosurgery peak surgical medtronic advanced energy medtronic
a first in human, dose escalation study of jab-3068 （shp2 inhibitor） in adult patients with advanced solid tumors

Conditions: Non-small Cell Lung Cancer; Head and Neck Cancer; Esophageal Cancer; Other Metastatic Solid Tumors

Summary: this is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of jab-3068 in adult patients with advanced solid.


Eligibility criteria:
inclusion criteria: 1. written informed consent obtained prior to any study-related procedure being performed; 2. age 18 years or older; 3. patients with histologically or cytologically confirmed, advanced solid tumors which have progressed despite standard therapy or for whom no standard therapy exists; 4. patients with life expectancy ≥3 months; 5. patients must have at least one measurable lesion as defined by recist v1.1; 6. eastern cooperative oncology group performance score 0 or 1; 7. patients who have sufficient baseline organ function. exclusion criteria: 1. patients with life-threatening autoimmune disease or with autoimmune disorder and who are on long-term steroid treatment; 2. history or current evidence of retinal vein occlusion (rvo) or current risk factors for rvo; 3. known malignant central nervous system (cns) disease other than neurologically stable, treated brain metastases; 4. active infection including hepatitis b, hepatitis c and human immunodeficiency virus (hiv) 5. patients who have any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator and sponsor, could affect the patient's participation in the study 6. patients who have impaired cardiac function or clinically significant cardiac diseases; 7. use of anti-cancer treatment drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of jab-3068; 8. use of an investigational drug during the past 30 days or 5 half-lives (whichever is shorter) prior to the first dose of jab-3068; 9. no other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy radiotherapy (except for palliative local radiotherapy), biological therapy or other novel agent is to be permitted while the patient is receiving study medication.

Keywords: jab-3068 shp2 advanced solid tumor nsclc escc hnscc ptpn11 egfr colorectal cancer
knowledge, attitude and practices regarding green eco-friendly dentistry among a group of dentists

Conditions: Knowledge, Attitudes, Practice

Summary: global warming, reduction in resources, increase in prices are all factors leading to more direction towards reuse, recycling, and reduction in use of materials. the world dental federation (fdi) considers sustainability to be an indispensable principle of dentistry, which "must be practiced ethically, with high levels of quality and safety, in the pursuit of optimal oral health. sustainability requires more attention from dental health professionals to reduce, recycle and reuse available resources.

the direction towards more reuse, recycling and reduction in the use of materials is a global direction. the egyptian society needs to address the concepts, however, there is lack of knowledge on the knowledge, attitude, and practices of egyptian dentists regarding green eco-friendly dentistry. research question: what is the knowledge, attitude, and practices of a group of dentists regarding green eco-friendly dentistry?

Eligibility criteria:
inclusion criteria: * graduated dentists. * dentists graduated from egyptian universities. exclusion criteria: * refusal of participation.

Keywords: green dentistry eco-friendly dentistry knowledge attitude practice
loncastixumab tesirine (adct-402) expanded access program (eap) for patients with relapsed/refractory diffuse large b-cell lymphoma

Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Summary: the eap is for patients with relapsed/refractory diffuse large b-cell lymphoma (r/r dlbcl) that cannot be treated by currently available drugs, cell therapy, or clinical trials. adc therapeutics will evaluate patients for approval into the program.


Eligibility criteria:
inclusion criteria: * male or female patient aged 18 years or older * pathologic diagnosis of dlbcl * relapsed/refractory diffuse large b-cell lymphoma (r/r dlbcl) that cannot be treated by currently available drugs, cell therapy, or clinical trials * women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least six months after the last dose of loncastuximab tesirine. men with female partners who are of childbearing potential must agree that they will use a highly effective method of contraception from the time of giving informed consent until at least six months after the patient receives his last dose of loncastuximab tesirine exclusion criteria: * known history of hypersensitivity to or positive serum human anti-drug antibodies to loncastuximab tesirine * total bilirubin \>1.5 x upper limit of normal (uln) * active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that adct head of medical affairs and/or designee, and treating physician agree and document should not be exclusionary * autologous stem cell transplantation (sct) within 30 days prior to start of loncastuximab tesirine * allogeneic sct within 60 days prior to start of loncastuximab tesirine * clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath) * lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease * breastfeeding or pregnant * major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to starting loncastuximab tesirine, except shorter if approved by adct * use of any other experimental medication within 14 days prior to starting loncastuximab tesirine * any other significant medical illness, abnormality, or condition that would, in the treating physician's judgment, make the patient inappropriate to receive loncastuximab tesirine or put the patient at risk

Keywords: expanded access lymphoma large b-cell relapsed refractory
clinical efficacy and safety evaluation of irbesartan and amlodipine combined therapy in essential hypertension patients

Conditions: Essential Hypertension

Summary: the purpose of this study is to evaluate efficacy and safety of irbesartan and amlodipine combined therapy in patients with essential hypertension inadequately controlled on irbesartan monotherapy


Eligibility criteria:
inclusion criteria: * patients who are 19 years or older on screening * signed informed consent * patients with essential hypertension * other inclusion applied exclusion criteria: * orthostatic hypotension * other exclusion applied
the clinical study on isoflavone genistein in restructuring the gut microbiota of hyperlipidemia patients

Conditions: Hyperlipidemia

Summary: : in preliminary animal experiments, we found that the soybean isoflavone compound genistein could reduce serum tmao levels in high-fat diet (hfd) mice, and this effect was dependent on the gut microbiota. furthermore, we discovered that genistein's regulatory effect on the gut microbiota in high-fat diet mice relies on the host colonic pki-nos2 pathway. genistein is an isoflavone compound extracted from soybeans and is the most effective functional ingredient in soybean isoflavone products. it has multiple physiological functions, and several randomized controlled trials (rcts) have shown that the intake of genistein can effectively alleviate hyperlipidemia, obesity, metabolic syndrome, and cardiovascular diseases, suggesting its safety and efficacy as a clinical health supplement. therefore, we aim to conduct clinical trials to further demonstrate that genistein also influences the gut microbiota in hyperlipidemia patients, thereby reducing serum tmao levels.


Eligibility criteria:
inclusion criteria: * aged between 30-65 years old, regardless of gender * abnormal donation and loan: including elevated total cholesterol and triglycerides, high triglycerides, and high triglycerides * volunteer to participate in clinical trials, understand and sign the informed consent form exclusion criteria: * patients who do not meet the inclusion criteria * patients with gastrointestinal or chronic infectious diseases (i.e., diarrhea, crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticular disease, gastric or duodenal ulcer, hepatitis, hiv, cancer, etc.), or with a history of such diseases * chronic or acute kidney disease, egfr \ 5.4 in two or more laboratory tests in the past 6 months) * severe immunodeficiency (hiv positive, transplant patients, taking anti-rejection drugs, taking steroids for \> 30 days, or receiving chemotherapy or radiotherapy in the past year) * alarm features such as weight loss, rectal bleeding, recent changes in bowel habits (\< 3 months), or abdominal pain * patients with malignant diseases or any concomitant end-stage organ diseases * patients who have taken any antibiotics or dietary supplements (prebiotics, probiotics, fiber, resveratrol, fish oil, seed oil, ginkgo leaf, ginseng, fruit powder extract and dha) within one month * patients who have taken any chinese patent medicine or chinese herbal decoction within one month * avoid eating seafood or fish 24 hours before each visit * vegetarian/vegan diet or food allergies or other food problems that will prevent the intake of research products * pregnant or preparing for pregnancy and breastfeeding women * allergic constitution, or known allergy to isoflavone genistein * participating in other drug clinical studies within 1 month * according to the investigator's judgment, the patient cannot complete this study or cannot comply with the requirements of this study (due to management reasons or other reasons)

Keywords: genistein hyperlipidemia gut microbiota tmao
rituximab and combination chemotherapy in treating patients with previously untreated mantle cell lymphoma

Conditions: Mantle-Cell Lymphoma

Summary: the investigator(s) hypothesize that rituximab together with combination chemotherapy, followed by rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients with previously untreated mantle cell lymphoma (mcl).


Eligibility criteria:
inclusion criteria: 1. previously untreated, histologically confirmed mantle cell lymphoma, 2. measurable or evaluable disease (at least one site with \>1.5 cm in diameter 3. all stages are eligible 4. age \> 18 years 5. eastern cooperative oncology group (ecog) performance status 0, 1, or 2 6. adequate hepatic function: * bilirubin \< 3 mg/dl * transaminases (serum glutamic oxaloacetic transaminase (sgot) and/or serum glutamate-pyruvate transaminase (sgpt)) \< than 2.5 times the upper limit of normal for the institution, unless due to lymphomatous involvement 7. serum creatinine\< 1.5 mg/dl 8. ability to give informed consent 9. women of childbearing potential must have a negative pregnancy test within 72 hours of entering into the study. males and females must agree to use adequate birth control if conception is possible during the study. women must avoid pregnancy and men avoid fathering children while in the study. 10. life expectancy greater than 6 months. exclusion criteria: 1. previous chemotherapy, immunotherapy or radiotherapy for this mantle cell lymphoma 2. concurrent active malignancies, with the exception of in situ carcinoma of the cervix and basal cell carcinoma of the skin. 3. grade 3 or 4 cardiac failure and/or ejection fraction \< 50. 4. psychological, familial, sociological or geographical conditions that do not permit treatment and/or medical follow-up required to comply with the study protocol. 5. patients with a known history of human immunodeficiency virus (hiv) or acquired immunodeficiency syndrome (aids). 6. presence of hepatitis or hepatitis b virus (hbv) infection. 7. pregnant or breast-feeding women. 8. central nervous system (cns) involvement.

Keywords: non-hodgkin's lymphoma mcl nhl
loop resectoscope in treating patients with bladder cancer or benign prostatic hyperplasia who are undergoing transurethral resection

Conditions: Bladder Cancer

Summary: rationale: transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. transurethral resection using a loop resectoscope may have fewer side effects and improve recovery. purpose: this clinical trial is studying how well the loop resectoscope works in treating patients with bladder cancer or benign prostatic hyperplasia who are undergoing transurethral resection.

objectives: * determine the efficacy, in terms of mechanical capabilities, of the roei loop resectoscope in patients with bladder cancer or benign prostatic hyperplasia undergoing transurethral resection of bladder tumor or benign prostatic adenoma. * determine the quality of specimens submitted for histological analysis from patients undergoing this procedure. outline: this is an open-label, pilot study. patients undergo transurethral resection using the roei loop resectoscope. surgeon satisfaction with the roei loop resectoscope is measured by a self-assessment questionnaire. the quality of specimens submitted for histological study are also assessed. projected accrual: a total of 24 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of bladder cancer or benign prostatic hyperplasia patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: recurrent bladder cancer stage i bladder cancer stage ii bladder cancer stage iii bladder cancer stage iv bladder cancer
efficacy and safety of mt-3995 in patients with non-alcoholic steatohepatitis(nash)

Conditions: NASH

Summary: the purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of multiple oral administration of mt-3995 in patients with nash.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with nash before randomization * subjects who conducts diet or exercise therapy at the beginning of run in period. * subjects who has given full and adequate information of the protocol and with written informed consent exclusion criteria: * subjects with hepatic failure or previously diagnosed with hepatic cirrhosis * subjects with alcohol dependence or previously diagnosed with alcohol dependence * subjects with other chronic liver disease (e.g., primary sclerosing cholangitis, alcoholic liver damage, hemochromatosis, wilson's disease) * presence, history, or family history of long qt syndrome or torsades de pointes * subjects with heart failure (new york heart association class iii-iv)

Keywords: nash
t2 weighted imaging of the liver with fast spin echo mri

Conditions: Liver Disease

Summary: the purpose of this study is to test two new mri (magnetic resonance imaging) sequences to see how they compare to previously used imaging sequences as they may improve the quality of abdominal mri.

* approximately 50 patients undergoing routine liver mri in our practice imaged with one of our 4 clinical scanners will undergo our standard liver mri protocol with the addition of 2 breath-hold sequences (fse flex and essfse) only increasing the scan time by approximately 3 minutes. * data will be retrieved from examinations that have been performed from the patient's electronic imaging file stored in our picture archiving and communication system (pacs). * images will be completely anonymized. no patient identifiers will be available on the images during the analysis. * analyses will include the visual assessment of image quality, presence and severity of imaging artifact and other non-invasive imaging outcomes performed by radiologists blinded to patient information and the type of sequence performed. data will be presented in a likert type scale (1=poor, 2=suboptimal, 3=average, 4=above average and 5=excellent) and imaging parameters will be compared using the wilcoxon sign rank test.

Eligibility criteria:
inclusion criteria: * patients undergoing routine liver mri imaged with one of our 4 clinical scanners (mr 750w, general electric, milwaukee wi) exclusion criteria: * patients not undergoing routine liver mri

Keywords: abdominal-pelvic mri (magnetic resonance image) t2w (t2 weighted) fse flex (recently developed mri pulse sequence) enhanced single shot fse (fast spin echo).
operation of a mobile telemedicine system in the ems

Conditions: Prehospital Emergency; Teleconsultation; Safety

Summary: the aim of the study is to investigate the safety and efficacy of the operation of a prehospital teleconsultation system in the emergency medical service.

six ambulances from five different emergency medical service (ems) districts are equipped with a portable telemedicine system. the paramedics can use this system to contact a so called "tele-ems physician" after consent of the patient is obtained. the tele-ems physician has an audio-connection to the ems team and receives vital parameters (e.g., ecg, pulse oximetry, non-invasive blood pressure) in real-time. also 12-lead-ecgs can be transmitted to the tele-ems physician. the transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. the tele-ems physician supports the ems team in obtaining all relevant medical history, ecg diagnosis, general diagnosis and can delegate the application of medications. this can be carried out to bridge the time to the arrival of an ems physician or in less severe cases without an ems physician on-scene. the safety and efficacy of the introduction and operation of this system should be evaluated.

Eligibility criteria:
inclusion criteria: * prehospital emergency * consent of the patient for teleconsultation was obtained or patient is unable to consent due to the severity of the emergency exclusion criteria: * patient refuses consent for teleconsultation * psychiatric emergency

Keywords: emergency medical service telemedicine teleconsultation safety